Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
How do you document body surface area or lesion burden for ruxolitinib coverage decisions?
1:04
Apr 2, 2026Atopic Dermatitis

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

-

When might ruxolitinib cream be appropriate earlier in the treatment pathway?
1:04
Apr 2, 2026Atopic Dermatitis

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

-

What is the single most meaningful management decision that becomes clearer after genomic testing?
0:45
Mar 6, 2026Precision Medicine

What is the single most meaningful management decision that becomes clearer after genomic testing?

-

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?
1:21
Mar 6, 2026Precision Medicine

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

-

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?
1:19
Mar 6, 2026Precision Medicine

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

-

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?
0:44
Mar 6, 2026Precision Medicine

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

-

What can AdvanceAD-TX tell you that clinical phenotype alone does not?
1:36
Mar 6, 2026Precision Medicine

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

-

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?
0:55
Mar 6, 2026Precision Medicine

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

-

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?
1:11
Mar 6, 2026Precision Medicine

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

-

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?
2:03
Mar 6, 2026Precision Medicine

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

-

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?
3:30
Mar 6, 2026Precision Medicine

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

-

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?
1:18
Mar 6, 2026Precision Medicine

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

-

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?
2:01
Mar 6, 2026Precision Medicine

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

-

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?
1:51
Mar 6, 2026Precision Medicine

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

-

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?
1:06
Mar 6, 2026Precision Medicine

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

-

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?
0:42
Mar 3, 2026Psoriasis

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

-

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?
0:44
Mar 3, 2026Psoriasis

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

-

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?
0:36
Mar 3, 2026Psoriasis

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

-

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?
0:41
Mar 3, 2026Psoriasis

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

-

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?
1:04
Mar 3, 2026Psoriasis

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

-

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?
0:51
Mar 3, 2026Psoriasis

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

-

What clinical details make an appeal letter more persuasive?
1:46
Mar 2, 2026Atopic Dermatitis

What clinical details make an appeal letter more persuasive?

-

What supporting materials help overturn a denial?
1:17
Mar 2, 2026Atopic Dermatitis

What supporting materials help overturn a denial?

-

When do you escalate from prior auth to formal appeal?
1:42
Mar 2, 2026Atopic Dermatitis

When do you escalate from prior auth to formal appeal?

-